New pituitary oncogenes.
Pituitary tumors are common monoclonal neoplasms which cause considerable morbidity and mortality. Several molecular events underlying pituitary tumorigenesis have been elucidated in recent years, but no tumor marker has clearly emerged which assists clinical and therapeutic decisions. Activating mutations and loss of inactivating mutations, together with hypothalamic hormones, circulating hormones, growth factors and cytokines cooperatively ensure the inexorable expansion of the initial mutated pituitary cell clone. This review describes new developments in our understanding of the molecular mechanisms involved in the pathogenesis of pituitary tumors. The availability of molecular probes will allow the early prediction of tumor behavior, identify targets for designing subcellular pituitary tumor therapy and provide novel approaches to pituitary tumor management.
Heaney
A P
AP
Department of Medicine, Cedars-Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA.
Melmed
S
S
D000818:Animals; D004967:Estrogens / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000502:physiology; D016147:Genes, Tumor Suppressor; D019942:Genes, p16; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics; D009389:Neovascularization, Pathologic / Q000209:etiology; D009857:Oncogenes; D010911:Pituitary Neoplasms / Q000209:etiology / Q000235:genetics*; D064249:Securin
D004967:Estrogens; D009363:Neoplasm Proteins; D064249:Securin; D016222:Fibroblast Growth Factor 2